Subscribe to RSS
DOI: 10.1055/s-0044-1787831
Chart Review and Practical Recommendations for the Use of Methadone as an Alternative to Opioid Rotation in the Management of Cancer-Related Pain
Abstract
Introduction Palliative care, with a focus on enhancing the quality of life for individuals facing life-limiting illnesses, relies on effective pain management as a fundamental component. Opioids, particularly methadone, play a crucial role in addressing moderate to severe pain in palliative care due to their unique pharmacological properties. Methadone, a long-acting opioid agonist and N-methyl-D-aspartate receptor antagonist, is valuable for treating both nociceptive and neuropathic pain. However, the transition to methadone from other opioids requires careful consideration.
Objectives This study examines the use of methadone as an alternative to morphine or fentanyl for managing refractory cancer pain in a tertiary care hospital in India.
Methods We conducted a retrospective analysis of anonymized medical records of cancer patients initiated on oral methadone for pain management at a tertiary cancer center's palliative medicine outpatient clinic from February 2020 to June 2021. Data included demographic characteristics, pain descriptions, concurrent analgesic use, reasons for transitioning to methadone, rotation methods, methadone dosages, clinical outcomes, adverse effects, and treatment discontinuations. Patients were routinely followed up, with pain scores, morphine equivalent daily doses, and methadone requirements recorded at each visit.
Results Forty-four patients received methadone, either as a coanalgesic (41/44) or primary opioid (3/44). Refractory cancer pain, with a neuropathic component, was the predominant indication for methadone use. Following the methadone initiation, all patients experienced significant pain relief. Median daily methadone dose increased from 5 to 7.5 mg after 1 week. Adverse effects were minimal, with one patient experiencing QTc interval prolongation. Patient-specific factors often necessitated deviations from equianalgesic conversion tables in determining methadone dosages.
Conclusion Methadone offers a viable option for refractory cancer pain when conventional treatments fall short. Physicians should prioritize personalized titration and thorough assessment during opioid rotation, rather than relying solely on conversion tables. Further research is needed to explore alternative approaches for opioid rotation and to expand our understanding of methadone's optimal use in cancer pain management.
Keywords
methadone - cancer pain - opioid rotation - equianalgesic conversion - pain relief - side effectsDisclosure
The responsibility for the writing and content of the article lies solely with the author.
Publication History
Article published online:
18 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 McLean AJ. Palliative care. Palliat Support Care 2017; 15 (05) 625
- 2 McPherson ML, Walker KA, Davis MP. et al. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 2019; 57 (03) 635-645.e4
- 3 Fredheim OMS, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008; 52 (07) 879-889
- 4 Kreutzwiser D, Tawfic QA. Methadone for pain management: a pharmacotherapeutic review. CNS Drugs 2020; 34 (08) 827-839
- 5 McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage 2015; 50 (02) 248-59.e1
- 6 Narcotic Drugs & Psychotropic Substances | Department of Revenue | Ministry of Finance | GoI. Accessed April 28, 2020, at: https://dor.gov.in/narcotic-drugs-psychotropic
- 7 Hanna V, Senderovich H. Methadone in Pain Management: A Systematic Review. J Pain 2021; Mar; 22 (03) 233-245
- 8 Indian against cancer. Statistics - India Against Cancer. Published online 2012
- 9 Palliative care for adults: strong opioids for pain relief. Palliative care for adults: strong opioids for pain relief. Published online 2016. Accessed August 26, 2023, at: https://www.ncbi.nlm.nih.gov/books/NBK555200/
- 10 Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev 2016; 4 (04) CD003868
- 11 Soares LGL, Martins M, Uchoa R. Intravenous fentanyl for cancer pain: a “fast titration” protocol for the emergency room. J Pain Symptom Manage 2003; 26 (03) 876-881
- 12 Quirk K, Stevenson M. Buprenorphine microdosing for the pain and palliative care clinician. J Palliat Med 2022; 25 (01) 145-154
- 13 Mercadante S. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Curr Med Res Opin 2017; 33 (11) 1965-1969
- 14 Gonçalves JAF, Silva P, Araújo P. Does tramadol have a role in pain control in palliative care?. Am J Hosp Palliat Care 2015; 32 (06) 631-633
- 15 Smith TJ, Hillner BE. The cost of pain. JAMA Netw Open 2019; 2 (04) e191532-e191532
- 16 India MART. (2024). Analgesic. Available at: https://dir.indiamart.com/search.mp?ss=analgesic&src=homepage&prdsrc=1&res=RC4
- 17 Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol 1998; 16 (10) 3216-3221
- 18 Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004; 12 (11) 762-766
- 19 Chou R, Cruciani RA, Fiellin DA. et al; American Pain Society, Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on problems of drug dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15 (04) 321-337
- 20 Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 2022; 71 (03) 1-95